With study success, AbbVie's arthritis hopeful looks to be a safer bet

AbbVie Inc.'s experimental arthritis drug upadacitinib succeeded in its fourth and largest-to-date Phase 3 study, beating out both placebo and the drugmaker's top-selling Humira in treating rheumatoid arthritis.